<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320667</url>
  </required_header>
  <id_info>
    <org_study_id>ANCAFLURINOCYTE</org_study_id>
    <nct_id>NCT04320667</nct_id>
  </id_info>
  <brief_title>Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis</brief_title>
  <official_title>Phenotype of Urinary CD4+ T Cells as Biomarkers for Prediction of Outcome in ANCA Glomerulonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlin Institute of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary T lymphocytes may be predictive for clinical outcome in patients with ANCA associated
      glomerulonephritis (ANCA GN). The investigators hypothesize that the amount of CD4+
      effector/memory T cells in urine at time of diagnosis predicts the outcome of patients with
      active ANCA GN after 6 months of therapy. In a prospective, six-months follow-up study
      patients' urine will be analysed by flow cytometry every 60 days (+/- 10d). Treatment will be
      performed to the discretion of the treating clinician. After 6 months of treatment response
      will be determined as either complete response or partial response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotype of CD4+ T cells at time point 0 predictive of clinical outcome in patients with active ANCA-assosciated glomerulonephritis</measure>
    <time_frame>6 months</time_frame>
    <description>Urinary CD4+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with active ANCA-assosciated glomerulonephritis. The frequency of effector/memory CD4+ T lymphocytes is higher in patients with non- or partial response.
Complete response at 24 weeks: BVAS = 0 Partial response at 24 weeks: at least one renal element of the BVAS score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of patients with persistent renal abnormalities as partial response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype of CD8+ T cells at time point 0 predictive of clinical outcome in patients with active ANCA-assosciated glomerulonephritis</measure>
    <time_frame>6 months</time_frame>
    <description>Urinary CD8+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with active ANCA-assosciated glomerulonephritis. The frequency of effector/memory CD8+ T lymphocytes is higher in patients with non- or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis according to treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of active glomerulonephritis in Patients with ANCA associated vasculitis</measure>
    <time_frame>6 months</time_frame>
    <description>Diagnosis according to initial T cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of complete or partial response according to normalization of the amount of urinary T cells at time point 2 and 4</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Glomerulonephritis Acute</condition>
  <arm_group>
    <arm_group_label>Active ANCA glomerulonephritis</arm_group_label>
    <description>Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow cytometry analysis of urine samples</intervention_name>
    <description>Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.
T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326</description>
    <arm_group_label>Active ANCA glomerulonephritis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine, lymphocytes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at medical wards of Charité Universitätsmedizin Berlin and University College
        London, The Royal Free Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Biopsy proven ANCA related glomerulonephritis

          -  In absence of biopsy clinical diagnosis of ANCA related glomerulonephritis

        Exclusion Criteria:

          -  Biopsy proven non-ANCA related kidney disease

          -  Active menstrual bleeding

          -  Urinary tract infection

          -  Kidney transplantation during observational period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Enghard, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luka Prskalo</last_name>
    <phone>+4917630130373</phone>
    <email>luka.prskalo@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Enghard, PD Dr. med.</last_name>
    <email>philipp.enghard@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <state>Deutschland</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luka Prskalo</last_name>
      <phone>+4917630130373</phone>
      <email>luka.prskalo@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Philipp Enghard, PD Dr. med.</last_name>
      <email>philipp.enghard@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Luka Prskalo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Enghard, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Salama, PhD</last_name>
      <email>alan.salama@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Enghard P, Rieder C, Kopetschke K, Klocke JR, Undeutsch R, Biesen R, Dragun D, Gollasch M, Schneider U, Aupperle K, Humrich JY, Hiepe F, Backhaus M, Radbruch AH, Burmester GR, Riemekasten G. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann Rheum Dis. 2014 Jan;73(1):277-83. doi: 10.1136/annrheumdis-2012-202784. Epub 2013 Mar 8.</citation>
    <PMID>23475982</PMID>
  </reference>
  <reference>
    <citation>Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009 Sep;60(9):2830-8. doi: 10.1002/art.24747.</citation>
    <PMID>19714581</PMID>
  </reference>
  <reference>
    <citation>Lieberthal JG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Maksimowicz-McKinnon K, Seo P, Specks U, Ytterberg SR, Merkel PA, Monach PA; Vasculitis Clinical Research Consortium. urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2013 May;40(5):674-83. doi: 10.3899/jrheum.120879. Epub 2013 Apr 1.</citation>
    <PMID>23547217</PMID>
  </reference>
  <reference>
    <citation>Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology (Oxford). 2012 Jan;51(1):100-9. doi: 10.1093/rheumatology/ker280. Epub 2011 Oct 29.</citation>
    <PMID>22039267</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Philipp Enghard</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</keyword>
  <keyword>Pauci-Immune Vasculitis</keyword>
  <keyword>Churg-Strauss Syndrome</keyword>
  <keyword>Granulomatosis with Polyangiitis</keyword>
  <keyword>Microscopic Polyangiitis</keyword>
  <keyword>urinary biomarker</keyword>
  <keyword>outcome</keyword>
  <keyword>prediction,</keyword>
  <keyword>urinary effector memory T lymphocytes</keyword>
  <keyword>glomerulonephritis</keyword>
  <keyword>non-invasive biomarker</keyword>
  <keyword>flow cytometry</keyword>
  <keyword>treatment outcome</keyword>
  <keyword>CD4-Positive T-Lymphocytes/immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

